Original title: Hepatocyte SLC31A1-dependent copper accumulation contributes to hepatic glucose and lipid metabolic disturbances through AMPKα1 inactivation
Yin-Qin Cheng, Min Wei, Le Yang, You-Yi Zhuang +1 · September 2026
Type 2 diabetes causes liver problems, including fat buildup and poor responses to insulin, the hormone that controls blood sugar. Researchers wanted to see if a liver protein named SLC31A1, which imports copper into cells, plays a role in these metabolic issues. They studied diabetic mice and stressed liver cells in dishes. They found that diabetic livers had higher SLC31A1 levels, which trapped too much copper inside cells and shut down a helpful metabolic regulator called AMPKα1An enzyme inside cells that acts like a master energy switch, turning on processes that burn energy and turning off those that store it, such as making sugar or fat.. When the researchers silenced SLC31A1, copper stopped piling up and AMPKα1 turned back on. This single fix helped the mice handle insulin and glucose much better. It lowered excess glucose production, helped the liver store sugar properly again, and cut down dangerous fat accumulation, swelling, oxidative stress, and overall liver damage. Stressed cells also showed less fat buildup and better sugar balance.
Imagine your kitchen sink has a faucet that lets in a steady trickle of water to keep things clean. Normally, that works fine. But if the faucet opens too wide, water starts pooling on the counter, spoiling food and making a mess. In this paper, SLC31A1 is the faucet that lets copper into liver cells, and when it opens too much, copper buildup disrupts a crucial energy regulator—like the water ruining the electrical panel under the sink—leading to problems with sugar and fat storage.
This matters because it suggests a new way that diet and metabolism are connected: excess copper buildup in the liver, driven by a specific copper-transporting protein called SLC31A1, can interfere with a key energy-regulating signal (AMPKα1), leading to higher blood sugar and fat accumulation. If confirmed, this opens the possibility of targeting copper metabolism as a treatment for insulin resistance and fatty liver disease, conditions that affect millions of people with obesity or type 2 diabetes.
The abstract does not establish whether copper accumulation alone causes metabolic dysfunction in humans, only in mice and liver cells. It also does not rule out other mechanisms besides AMPKα1 inactivation, as the effect of AMPKα1 depletion or inhibition was only partial. The study does not address how generalizable the findings are to other tissues or to diabetes without HFD/STZ induction.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Hepatocyte SLC31A1-dependent copper accumulation contributes to hepatic glucose and lipid metabolic disturbances through AMPKα1 inactivation — Yin-Qin Cheng, Min Wei, Le Yang et al. — Biochemistry and biophysics reports — doi:10.1016/j.bbrep.2026.102787
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper.